Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients
| Status: | Completed |
|---|---|
| Conditions: | Cardiology, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/11/2018 |
| Start Date: | November 2012 |
| End Date: | December 2017 |
The same initial and long-term anticoagulation is suggested for unsuspected pulmonary
embolism as for patients with symptomatic embolism. Based on these indications, cancer
patients with unsuspected pulmonary embolism would be anticoagulated for at least 6 months or
until the disease is active, which in most cases would mean indefinite treatment. In fact,
dedicated studies on the treatment of unsuspected pulmonary embolism are missing, leaving
doubts over the need for (indefinite) anticoagulation which exposes these patients to an
increased risk of major bleeding events. Concerns over the need for anticoagulant treatment
may especially hold for pulmonary embolism of the distal pulmonary tree since segmental and
sub-segmental PE seem to have a more benign course than more proximal embolism.
The scope of this study is to evaluate the current treatment approaches for unsuspected
pulmonary embolism and to assess their efficacy and safety in a large prospective cohort of
cancer patients.
embolism as for patients with symptomatic embolism. Based on these indications, cancer
patients with unsuspected pulmonary embolism would be anticoagulated for at least 6 months or
until the disease is active, which in most cases would mean indefinite treatment. In fact,
dedicated studies on the treatment of unsuspected pulmonary embolism are missing, leaving
doubts over the need for (indefinite) anticoagulation which exposes these patients to an
increased risk of major bleeding events. Concerns over the need for anticoagulant treatment
may especially hold for pulmonary embolism of the distal pulmonary tree since segmental and
sub-segmental PE seem to have a more benign course than more proximal embolism.
The scope of this study is to evaluate the current treatment approaches for unsuspected
pulmonary embolism and to assess their efficacy and safety in a large prospective cohort of
cancer patients.
Inclusion Criteria:
- cancer patients with a first diagnosis of unsuspected PE
Exclusion Criteria:
1. age <18 years;
2. ongoing anticoagulant therapy for previous VTE or indications for long-term
anticoagulation other than deep vein thrombosis (DVT) or PE;
3. life expectancy less than 3 months.
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials